SCHEMBL441602

SCHEMBL441602

Clc1cc2nc(Br)[nH]c2cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.53
HTT P42858 1/20 0.53
RHEB Q15382 2/20 0.49
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
LMNA P02545 1/20 0.47
GRIK1 P39086 1/20 0.47
GRIA1 P42261 1/20 0.47
GRIA2 P42262 1/20 0.47
GRIA3 P42263 1/20 0.47
GRIA4 P48058 1/20 0.47
GRIN1 Q05586 1/20 0.47
GRIN2A Q12879 1/20 0.47
GRIK2 Q13002 1/20 0.47
GRIK3 Q13003 1/20 0.47
GRIN2B Q13224 1/20 0.47
GRIN2C Q14957 1/20 0.47
GRIK4 Q16099 1/20 0.47
GRIK5 Q16478 1/20 0.47
GRIN3A Q8TCU5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30860105 1.00 GAA (0.53) GAAHTTRHEBGRIN2DGRIN3B
Benzimidazole SCHEMBL7020475 0.80 PDE10A (0.42) GAAHTTRHEBGRIN2DGRIN3B
SCHEMBL577623 0.77 GAA (0.57) GAAHTTRHEBGRIN2DGRIN3B
SCHEMBL15825576 0.77 AMY1A (0.33) GAAHTTLMNAMEN1RAB9A
SCHEMBL9305390 0.75 GAA (0.43) GAAHTTRHEBGRIN2DGRIN3B
SCHEMBL9305399 0.75 GAA (0.43) GAAHTTGRIN2DGRIN3BLMNA
SCHEMBL9305060 0.75 ALDH1A1 (0.61) MEN1NPC1RAB9AKMT2A
SCHEMBL9305046 0.75 F7 (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1006779 0.74 FABP6 (0.59) MEN1NPC1RAB9AKMT2AHRH4
SCHEMBL7393275 0.74 GAA (0.53) GAAHTTRHEBGRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7375235-B2 Process for preparing substituted benzimidazole compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-05-20 US claimed
US-20050261211-A1 Process for preparing substituted benzimidazole compounds GLAXOSMITHKLINE LLC 2005-11-24 US claimed
EP-1584620-A1 Process for preparing substituted benzimidazole compounds GLAXO GROUP LIMITED (GB) 2005-10-12 EP claimed
EP-1272473-B1 PROCESS FOR PREPARING SUBSTITUTED BENZIMIDAZOLE COMPOUNDS GLAXO GROUP LTD (GB) 2005-06-29 EP claimed
JP-2003530385-A 2003-10-14 JP claimed
US-20030191127-A1 Process for preparing substituted benzimidazole compounds GLAXOSMITHKLINE LLC 2003-10-09 US claimed
EP-1272473-A1 PROCESS FOR PREPARING SUBSTITUTED BENZIMIDAZOLE COMPOUNDS GLAXO GROUP LIMITED (GB) 2003-01-08 EP claimed
EP-0845001-B1 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS UNIV MICHIGAN (US) 2002-11-13 EP claimed
WO-2001077083-A1 PROCESS FOR PREPARING SUBSTITUTED BENZIMIDAZOLE COMPOUNDS GLAXO GROUP LIMITED (GB) 2001-10-18 WO claimed
US-5874413-A CYTOMEGALO VIRUS UNIVERSITY OF MICHIGAN (US) 1999-02-23 US claimed
US-20260108495-A1 VIRAL INHIBITORS, THE SYNTHESIS THEROF, AND INTERMEDIATES THERETO TAKEDA PHARMACEUTICALS CO (JP) 2026-04-23 US disclosed
US-20260097018-A1 VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-04-09 US disclosed
US-20260076946-A1 VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-03-19 US disclosed
US-20260076945-A1 VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-03-19 US disclosed
US-12527771-B2 Viral inhibitors, the synthesis thereof, and intermediates thereto TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-01-20 US disclosed
US-5360795-A Treating cytomegalo virus and herpes simplex viruses THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1994-11-01 US disclosed
WO-1994008456-A1 POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1994-04-28 WO disclosed
US-5248672-A POLYSUBSTITUTED BENZIMIDAZOLE NUCLEOSIDES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1993-09-28 US disclosed
EP-0556334-A1 POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1993-08-25 EP disclosed
WO-1992007867-A1 POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1992-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260076946-A1 VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO TPMT, MPST, PCMT1 GAA 2561/4885HTT 2378/4885RHEB 493/4885
US-12527771-B2 Viral inhibitors, the synthesis thereof, and intermediates thereto IRF3, RPL12, MCM4 GAA 1589/4885HTT 4624/4885RHEB 858/4885
US-20260097018-A1 VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO TPMT, PCMT1, RPL7 GAA 2824/4885HTT 2995/4885RHEB 1588/4885
US-20260076945-A1 VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO PCMT1, MPST, TPMT GAA 2387/4885HTT 2561/4885RHEB 1385/4885
US-20030191127-A1 Process for preparing substituted benzimidazole compounds EIF2AK2, SAMHD1, ZC3HAV1 GAA 200/4885HTT 4194/4885RHEB 3074/4885
US-20050261211-A1 Process for preparing substituted benzimidazole compounds EIF2AK2, SAMHD1, ZC3HAV1 GAA 200/4885HTT 4194/4885RHEB 3074/4885
US-20260108495-A1 VIRAL INHIBITORS, THE SYNTHESIS THEROF, AND INTERMEDIATES THERETO HYOU1, CYP2F1, HAVCR2 GAA 524/4885HTT 1729/4885RHEB 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.